

Media contact:

HRA Pharma

Karina Gajek

+33 1 40 33 66 02

k.gajek@hra-pharma.com

Carilène

Stephane Desjonquieres

+33 1 30 15 58 92

stephane.desjonquieres@carilene.fr

HRA Pharma and Laboratoires Carilene Sign an Exclusive Distribution Agreement for a Product Indicated in the Symptomatic Treatment of Genital Herpes

The agreement covers all the 28 countries of the European Union plus Switzerland, Norway and Turkey.

Paris, France -October 31, 2013 - HRA Pharma, a global pharmaceutical company specialized in women's health and endocrinology, and Laboratoires Carilene, a laboratory specialized in the development of medical devices, announced today that they have signed an exclusive distribution agreement for an innovative treatment of genital herpes. Under the terms of the agreement, HRA Pharma will have the exclusive rights to market this treatment throughout all the 28 countries of the European Union plus Switzerland, Norway and Turkey.

Genital herpes is a sexually transmitted infection that affects 35 million people in Europe and is rapidly increasing worldwide. The product is a local treatment that, if applied when the first symptoms appear, relieves pain, significantly reduces burning and the duration of herpes crisis. HRA Pharma expects to launch the product on the market in the second half of 2014.

Erin Gainer, CEO of HRA Pharma, said "HRA Pharma is pleased to work with Carilene to establish this product as a gold standard in the local treatment of genital herpes symptoms. The international reputation of HRA Pharma as an innovative actor in women's health, as well as our knowledge of the European pharmaceutical market will help us to develop the full potential of this treatment in the target markets. "

Stéphane Desjonquieres, CEO of Laboratoires Carilene confirms "We are very pleased to have entered into this European partnership with HRA Pharma. This agreement will allow a product, which has focused our research efforts for several years, to reach the European market. HRA Pharma, a specialty pharmaceutical company, centered on women health and endocrinology, will bring to our product its promotional and distribution network as well as its scientific expertise."

About HRA Pharma

HRA Pharma is an international specialty healthcare company dedicated to women's health and endocrinology. Headquartered in Paris - France, the company has a direct presence in France, Spain, United Kingdom, Ireland, Germany, Italy and Switzerland; and is looking at opportunities to further expand its international footprint through organic growth and strategic partnerships. Committed to serving needs everywhere, the company has built a strong network of R&D, manufacturing, distribution and NGO partners which enables it to improve patient health in over 50 countries across the globe. Visit www.hrpharma.com for more information.

About Laboratoires Carilene

Laboratoires Carilene dedicated to the development of medical devices has been founded in 1982. Their research is centered on original criteria of vegetable oils fatty acids treated by specific oxygenation, the Oxidised Glycerol Triester (OGT). Numbers of European and American patents have been issued followed by publications in scientific journals. In addition to herpes, Laboratoires Carilene have brought an important contribution to bedsore prevention, xerostomia and lesions of the mucous membranes. Their products are distributed all over Europe and for some of them in USA and South America. Visit www.carilene.fr

About genital herpes

Genital herpes is a sexually transmitted and recurrent viral infection mainly caused by the Herpes simplex virus type 2 (HSV-2). Highly contagious, it affects genital organs and surrounding areas, significantly disrupting the sexual life and quality of life of patients. In Europe between 5 and 20% of adult population is infected with HSV-2, which is responsible for 90% cases of genital herpes. Widely underdiagnosed, genital herpes affects 35 million people in Europe, among which only 20% are treated (1, 2).

(1) Pebody RG, Andrews N, Brown D, et al. (2004). "The seroepidemiology of herpes simplex virus type 1 and 2 in Europe". *Sex Transm Infect* 80 (3): 185–91.

(2) Malkin JE (2004). "Epidemiology of genital herpes simplex virus infection in developed countries" (PDF). *Herpes. 11 Suppl 1: 2A–23A*

This product is a Class IIa Medical Device (MD), which is CE marked according to the regulation of MD (Notified body 1014)

Fabricant : Laboratoires CARILENE – 7, rue du Chant des Oiseaux – 78360 Montesson, France

Distributeur : HRA PHARMA – 15, rue Béranger – 75003 Paris, France